PVRIG and breast cancer: Supporting this hypothesis, when compared with neutralization of TIGIT or CD112R individually, dual blockade of these receptors resulted in improved human NK cell antibody-dependent cellular cytotoxicity (ADCC) against trastuzumab-coated breast cancer cells in vitro [41].